temozolomide has been researched along with Brain Diseases in 9 studies
Brain Diseases: Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Radiation therapy and concomitant temozolomide chemotherapy are commonly used in treatment of brain tumors, but they may also result in behavioral impairments such as anxiety and cognitive deficit." | 7.91 | Fluoxetine reverses brain radiation and temozolomide-induced anxiety and spatial learning and memory defect in mice. ( Chai, D; Gan, H; Wu, S; Zhang, Q; Zhu, B, 2019) |
| "Paclitaxel is an antineoplastic agent that is used in the treatment of a variety of solid tumors." | 5.35 | Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma. ( Fangusaro, J; Finlay, J; Rook, J; Rosser, T, 2008) |
| "Pseudoprogression constitutes a typical posttherapeutic phenomenon in patients with glioblastoma treated with radiochemotherapy with temozolomide." | 4.90 | Neuroimaging of therapy-associated brain tissue abnormalities. ( Linn, J, 2014) |
| "Radiation therapy and concomitant temozolomide chemotherapy are commonly used in treatment of brain tumors, but they may also result in behavioral impairments such as anxiety and cognitive deficit." | 3.91 | Fluoxetine reverses brain radiation and temozolomide-induced anxiety and spatial learning and memory defect in mice. ( Chai, D; Gan, H; Wu, S; Zhang, Q; Zhu, B, 2019) |
| "We retrospectively identified 68 consecutive patients with high-grade gliomas treated by surgical resection followed by radiation therapy and temozolomide, who then developed increasing enhancing mass lesions indeterminate for treatment-related changes versus recurrent tumor." | 3.81 | Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. ( Beal, K; Martinez, N; Omuro, A; Prager, AJ; Young, RJ; Zhang, Z, 2015) |
| "Standard therapy for glioblastoma (GBM) is temozolomide (TMZ) administration, initially concurrent with radiotherapy (RT), and subsequently as maintenance therapy." | 3.74 | MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. ( Andreoli, A; Bartolini, S; Bertorelle, R; Blatt, V; Brandes, AA; Calbucci, F; Ermani, M; Franceschi, E; Frezza, G; Leonardi, M; Pession, A; Spagnolli, F; Tallini, G; Tosoni, A, 2008) |
| "The prime challenge in treatment of brain disorders is to deliver therapeutics by overcoming the blood-brain barrier (BBB), a unique anatomical and physiological barrier which restricts the passage of a number of molecules, proteins, and cells from the bloodstream." | 1.56 | Lipid Nanocarriers for Enhanced Delivery of Temozolomide to the Brain. ( Dubey, SK; Khosa, A; Krishna, KV; Saha, RN, 2020) |
| "Temozolomide (TMZ) has established antineoplastic activity in the central nervous system in other disease states, with a favorable toxicity profile." | 1.51 | Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma. ( Brenner, A; Butler, MJ; Faivre, G; Le, I, 2019) |
| "Paclitaxel is an antineoplastic agent that is used in the treatment of a variety of solid tumors." | 1.35 | Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma. ( Fangusaro, J; Finlay, J; Rook, J; Rosser, T, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Khosa, A | 1 |
| Krishna, KV | 1 |
| Dubey, SK | 1 |
| Saha, RN | 1 |
| Gan, H | 1 |
| Zhang, Q | 1 |
| Zhu, B | 1 |
| Wu, S | 1 |
| Chai, D | 1 |
| Faivre, G | 1 |
| Butler, MJ | 1 |
| Le, I | 1 |
| Brenner, A | 1 |
| Linn, J | 1 |
| Prager, AJ | 1 |
| Martinez, N | 1 |
| Beal, K | 1 |
| Omuro, A | 1 |
| Zhang, Z | 1 |
| Young, RJ | 1 |
| Dixit, S | 1 |
| Salvage, D | 1 |
| Rajaraman, C | 1 |
| Hingorani, M | 1 |
| Rowland-Hill, C | 1 |
| Brown, GD | 1 |
| Luthra, SK | 1 |
| Brock, CS | 1 |
| Stevens, MF | 1 |
| Price, PM | 1 |
| Brady, F | 1 |
| Rook, J | 1 |
| Rosser, T | 1 |
| Fangusaro, J | 1 |
| Finlay, J | 1 |
| Brandes, AA | 1 |
| Franceschi, E | 1 |
| Tosoni, A | 1 |
| Blatt, V | 1 |
| Pession, A | 1 |
| Tallini, G | 1 |
| Bertorelle, R | 1 |
| Bartolini, S | 1 |
| Calbucci, F | 1 |
| Andreoli, A | 1 |
| Frezza, G | 1 |
| Leonardi, M | 1 |
| Spagnolli, F | 1 |
| Ermani, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Imaging After Stereotactic Radiosurgery for Brain Metastases or Primary Tumor Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease ?[NCT03068520] | 140 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for temozolomide and Brain Diseases
| Article | Year |
|---|---|
Neuroimaging of therapy-associated brain tissue abnormalities.
Topics: Antineoplastic Agents, Alkylating; Brain Diseases; Chemoradiotherapy; Dacarbazine; Glioblastoma; Hum | 2014 |
8 other studies available for temozolomide and Brain Diseases
| Article | Year |
|---|---|
Lipid Nanocarriers for Enhanced Delivery of Temozolomide to the Brain.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Diseases; Chromatography, Liq | 2020 |
Fluoxetine reverses brain radiation and temozolomide-induced anxiety and spatial learning and memory defect in mice.
Topics: Animals; Anti-Anxiety Agents; Antineoplastic Agents, Alkylating; Anxiety; Brain Diseases; Chemoradio | 2019 |
Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Disea | 2019 |
Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.
Topics: Aged; Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Dacarbazine; Disease Progression; Fema | 2015 |
Hypernatremia-associated myelinolysis following the management of sepsis in a patient with glioblastoma treated with radiotherapy and temozolomide.
Topics: Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Carcinoma; Carcinoma, Papillary; Dacarbazine | 2013 |
Antitumor imidazotetrazines. 40. Radiosyntheses of [4-11C-carbonyl]- and [3-N-11C-methyl]-8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (temozolomide) for positron emission tomography (PET) studies.
Topics: Antineoplastic Agents; Brain Diseases; Carbon Radioisotopes; Cyclization; Dacarbazine; Gas Chromatog | 2002 |
Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain | 2008 |
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Brain Neoplasms; Chemotherapy, Adjuv | 2008 |